Welcome to our dedicated page for Nanobiotix S.A. news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. stock.
Nanobiotix S.A. (NBTX) news covers developments at a late-stage clinical biotechnology company that focuses on physics-based therapeutic approaches and nanotechnology platforms. As a dual-listed issuer on Euronext Paris and the Nasdaq Global Select Market, Nanobiotix regularly publishes updates that are relevant to investors following oncology-focused biotechnology and pharmaceutical preparation manufacturing.
Company news frequently highlights progress in the JNJ-1900 (NBTXR3) clinical program, including updates on the global Phase 3 NANORAY-312 study in locally advanced head and neck squamous cell cancers and Phase 1 and Phase 2 studies sponsored by Nanobiotix or The University of Texas MD Anderson Cancer Center. Releases may also describe regulatory designations, collaboration milestones with Janssen Pharmaceutica NV, and the transfer of sponsorship and operational control of key trials.
Another recurring theme in Nanobiotix news is the Curadigm Nanoprimer platform. The company reports on new patent applications, preclinical in vivo data, and Chemistry, Manufacturing, and Controls (CMC) activities, as well as material transfer agreements with biotechnology and pharmaceutical partners evaluating Nanoprimer combinations with intravenously administered therapeutics.
Investors can also find announcements related to capital markets activity, such as royalty-based financing agreements with HealthCare Royalty (HCRx), inclusion in the CAC Mid 60 and SBF 120 indices on Euronext Paris, and periodic disclosures on shares outstanding and voting rights under French regulations. In addition, Nanobiotix issues notices about participation in investor and healthcare conferences, where management presents the company’s strategy and clinical pipeline.
By following NBTX news, readers can track clinical, financial, and strategic updates that shape the company’s development trajectory and its work in oncology, drug bioavailability and biodistribution, and central nervous system disorder applications.
NANOBIOTIX (NASDAQ: NBTX) reported full‑year 2025 results and a business update on March 31, 2026. Key highlights: €52.8M cash at year‑end with runway into early 2028 assuming receipt of the remaining $21M from a $71M royalty financing; €32.6M revenue; €24.0M net loss (−65% YoY).
Clinical progress included regulatory reclassification of JNJ‑1900 (NBTXR3), transfer of NANORAY‑312 sponsorship, CONVERGE dosing/data, multiple Phase 1/2 readouts, and Curadigm Nanoprimer IP/CMC advances. Conference call scheduled April 1, 2026.
NANOBIOTIX (NASDAQ: NBTX) announced first data from the Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3) in stage 3 inoperable non-small cell lung cancer, presented March 30, 2026 at the 2026 European Lung Cancer Conference.
The poster reports an acceptable safety profile with no serious treatment-emergent adverse events and no adverse impact on patients' ability to continue planned therapy. Initial efficacy in seven patients showed ORR 71.4% and DCR 100%, compared with an estimated benchmark ORR of 45%–50%.
NANOBIOTIX (NASDAQ: NBTX) will report its fourth quarter and full year 2025 operational and financial results on March 31, 2026, after U.S. market close. A conference call and webcast will be held on April 1, 2026 at 8:00 AM EDT / 2:00 PM CEST.
Laurent Levy, CEO, and Bart van Rhijn, chief financial and business officer, will review year-end results and provide a business update. Webcast replay will be archived on the company website; investors may submit questions in advance via email.
NANOBIOTIX (NASDAQ: NBTX) issued a statement on March 25, 2026 addressing recent media speculation about a potential public take-over.
The company said, to its knowledge, there is no intention by any party to acquire control and no process or assessment is underway; it also identified factual inaccuracies in the report that conflict with its recent public disclosures.
Nanobiotix (Nasdaq: NBTX) disclosed its voting rights and share capital as of February 28, 2026. The company reported 48,494,528 shares outstanding, 50,197,214 theoretical voting rights, and 50,175,096 exercisable voting rights.
Listing: Euronext Paris and Nasdaq; document explains calculation of gross and net voting rights under AMF rules.
NANOBIOTIX (NASDAQ: NBTX) announced management will attend multiple investor conferences in March 2026, including TD Cowen Health Care, UBS Biotech Summit Miami, Jefferies Biotech on the Beach, and Leerink's Global Healthcare Conference.
Presenters Laurent Levy, CEO, and Bart van Rhijn, CFO & Business Officer, will host scheduled fireside chats on March 4 and March 11, 2026, with locations in Boston and Miami Beach and specific times listed for investor access.
Nanobiotix (NASDAQ: NBTX) disclosed its voting rights and share count as of January 31, 2026. The company reported 48,450,358 shares outstanding, 50,153,460 theoretical voting rights and 50,131,342 exercisable voting rights.
The release explains methodology for theoretical vs exercisable voting rights and lists contact details for investor and media relations.
Nanobiotix (Ticker: NBTX) reported its share and voting-rights counts as of December 31, 2025 in accordance with French disclosure rules.
The company shows 48,410,068 shares outstanding and a total theoretical number of voting rights of 50,109,170, with 50,087,052 exercisable voting rights.
NANOBIOTIX (NASDAQ: NBTX) disclosed its voting rights and share capital as of November 30, 2025. The company reported 48,401,118 shares outstanding, 50,101,699 theoretical (gross) voting rights and 50,079,581 exercisable (net) voting rights.
Disclosure follows French legal requirements (articles L.233-8 II and AMF Article 223-16). NANOBIOTIX is listed on Euronext Paris and Nasdaq Global Select Market and holds over 25 patent families across three nanotechnology platforms with operations in France and the United States.
NANOBIOTIX (Euronext: NANO / NASDAQ: NBTX) will be admitted to the CAC Mid 60 and SBF 120 indices on Euronext Paris, effective after market close on December 19, 2025. The company said the index inclusions follow Euronext Paris's annual review.
The announcement notes inclusion is expected to broaden visibility among institutional investors, strengthen the company’s presence in European equity markets, and increase exposure to index-linked investment strategies. Management framed the move as validation of the company’s long-term strategy as it advances late-stage clinical programs in physics-based oncology.